News
In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the American Association for Cancer Research, Verily’s Parkinson’s dataset, the ...
2h
Zacks Investment Research on MSNGSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff ReassuranceGSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American depositary share (ADS), which beat the Zacks ...
As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the ...
Amid sweeping budget cuts and layoffs, HHS Secretary Robert F. Kennedy Jr. is planning a $20 million ad campaign urging ...
Novavax's protein-only vaccine is once again expected to move from emergency approval to full approval status following a pause.
Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...
Public health experts worried about the future of vaccination in the US have come together in an unprecedented new initiative ...
GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts ...
Here are eight possible indicators of how health secretary Robert F. Kennedy Jr. may handle U.S. vaccine policy in coming ...
In an interview with Dr. Phil, the Kennedy offered false information about vaccine oversight and revealed a lack of understanding of new drug approvals.
The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results